DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus

Phase 1

Active, not recruiting

Conditions: Type 2 Diabetes Mellitus (T2DM)
Obesity

Interventions: Drug: Rosuvastatin
Drug: Placebo
Drug: Midazolam
Drug: Omeprazole
Drug: PF-06954522

First Posted Date: 2024-02-28

Last Posted Date: 2025-02-13

Lead Sponsor: Pfizer

Target Recruit Count: 45

Registration Number: NCT06279234

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States

Litfulo Capsules Special Investigation

Active, not recruiting

Conditions: Alopecia Areata

Interventions: Drug: LITFULO

First Posted Date: 2024-02-28

Last Posted Date: 2025-03-13

Lead Sponsor: Pfizer

Target Recruit Count: 191

Registration Number: NCT06279221

Locations: 🇯🇵
Pfizer, Tokyo, Japan

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Completed

Conditions: Non-Small Cell Lung Carcinoma

Interventions: Drug: Lorlatinib

First Posted Date: 2024-02-28

Last Posted Date: 2024-02-28

Lead Sponsor: Pfizer

Target Recruit Count: 73

Registration Number: NCT06282991

Locations: 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳
CHANG GUNG MEMORIAL HOSPITAL Kaohsiung Branch, Kaohsiung City, Taiwan

and more 3 locations

A Study to Learn How Different Forms of Study Medicine Tafamidis Are Taken Up Into The Blood in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tafamidis 61 mg free acid tablet (Test 1)
Drug: Tafamidis 70 mg free acid tablet (Test 1)
Drug: Tafamidis 61 mg free acid capsule (Reference)

First Posted Date: 2024-02-23

Last Posted Date: 2024-06-26

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT06273839

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: vepdegestrant
Drug: esomeprazole

First Posted Date: 2024-02-23

Last Posted Date: 2024-06-03

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT06275841

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Oral [14C]PF-07220060
Drug: Oral PF-07220060
Drug: IV [14C] PF-07220060

First Posted Date: 2024-02-20

Last Posted Date: 2024-05-14

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT06267963

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Midazolam
Drug: Vepdegestrant

First Posted Date: 2024-02-13

Last Posted Date: 2025-01-21

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT06256510

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

Phase 2

Completed

Conditions: SARS-CoV-2 Infection
COVID-19
Influenza, Human

Interventions: Biological: BNT162b2 (Omi XBB.1.5)
Biological: RIV
Biological: BNT162b2 (Omi XBB.1.5)/RIV
Other: Normal saline placebo

First Posted Date: 2024-02-01

Last Posted Date: 2024-10-03

Lead Sponsor: Pfizer

Target Recruit Count: 645

Registration Number: NCT06237049

Locations: 🇺🇸
GW Vaccine Research Unit, Washington, District of Columbia, United States
🇺🇸
Optimal Research, Peoria, Illinois, United States
🇺🇸
GW Medical Faculty Associates, Washington, District of Columbia, United States

and more 24 locations

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab
Drug: Iberdomide

First Posted Date: 2024-01-22

Last Posted Date: 2025-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 87

Registration Number: NCT06215118

Locations: 🇦🇺
Calvary Mater Newcastle, Waratah, New South Wales, Australia
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

and more 28 locations

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: vepdegestrant
Drug: PF-07220060

First Posted Date: 2024-01-16

Last Posted Date: 2025-05-01

Lead Sponsor: Pfizer

Target Recruit Count: 65

Registration Number: NCT06206837

Locations: 🇺🇸
Highlands Oncology, Rogers, Arkansas, United States
🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸
Hoag Health Center Irvine, Irvine, California, United States

and more 50 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy